Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 24th Preview)
-
Huntington’s RNAi therapy shows early target knockdown
Alnylam reported early clinical data for brezosiran, its investigational RNAi therapy for Huntington’s disease, with patients receiving the highest dose showing about 60% to 64% average reductions in mutant huntingtin levels in cerebrospinal fluid across assay types. The company characterized the safety and tolerability profile as encouraging. Alnylam said it plans to start a placebo-controlled study next year to test whether brezosiran can slow disease progression, moving beyond biomarker readouts. The update was presented at the European Huntington’s Disease Network Clinical Research Congress. For the field, the key near-term question is whether deeper or more durable knockdown translates into measurable clinical slowing, not just target engagement. brezosiran joins a growing set of neurogenetic and RNA-based strategies competing on measurable biomarker endpoints in early studies.
-
Autoimmune CAR-T trial death raises safety scrutiny
Bristol Myers Squibb disclosed that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trial targeting multiple sclerosis, citing septic pneumonia that followed motor symptoms not resolving with standard autoimmune treatments. The event adds to heightened safety attention in autoimmune CAR-T programs after earlier pauses and disclosures by developers. BMS previously paused similar autoimmune studies after observing transient and reversible inflammatory events during routine surveillance. Around the same time, Novartis disclosed deaths in autoimmune CAR-T studies linked to an overactive immune condition. For developers, the central issue is whether dosing, disease-selection criteria, bridging strategies, or management protocols can reduce treatment-related severe inflammatory toxicity while preserving the therapeutic signal. Regulators and investigators are likely to intensify monitoring expectations for immune overactivation in this platform class.
-
Roche signs up Zymeworks for DLL3 T-cell engager
Roche moved to expand its trispecific T-cell engager pipeline by licensing Zymeworks’ ZW209, a DLL3-targeting construct designed to engage CD3 and CD28. The deal includes a $55 million upfront payment, with a further $40 million tied to initiating a Phase Ib program, plus up to $813 million in additional milestones. Zymeworks retains financial interest while Roche takes over worldwide development and commercialization under the agreement. The program is positioned against other DLL3-directed cell therapy efforts, including approaches in the competitive lung cancer immunotherapy landscape. The transaction underscores continued pharma appetite for early, differentiated multispecific platforms that can offer deeper or more durable responses if clinical activity holds up in later-stage trials.
-
Gilead buys PepStar oral IL-23R inhibitor for $1.275B
Gilead agreed to acquire PepStar Therapeutics’ oral IL-23 receptor inhibitor program, including the Phase 1 asset HCXT-2001, in a deal valued at $1.275 billion upfront. Gilead will gain worldwide rights to the oral macrocyclic peptide and is positioning it as a differentiated daily option for inflammatory bowel disease. Gilead said HCXT-2001 is designed as an oral IL-23 pathway blockade, potentially complementing or combining with Gilead’s broader inflammation portfolio, including emvistegrast. The company framed the move as expanding its inflammation and immunology pipeline with a new modality aimed at improving unmet needs. For PepStar, the acquisition marks a fast translation step for an early-stage oral biologic-like program; for Gilead, it adds a systemic but patient-convenience-focused alternative in a crowded IL-23-targeting market.
-
FDA accelerates dostarlimab for MSI-H/dMMR locally advanced rectal cancer
The FDA granted accelerated approval to dostarlimab (Jemperli) for adults with stage II or III locally advanced rectal cancer whose tumors are MSI-H or mismatch repair-deficient. The decision is based on AZUR-1, a multicenter, single-arm, open-label trial evaluating dostarlimab in previously untreated patients. In AZUR-1, investigators reported a 12-month clinical complete response rate of 47% among evaluable patients by independent central review, alongside a 79% objective response rate. After a median follow-up of 26.3 months, the report said patients achieving clinical complete response did not experience disease progression. Clinically, the approval expands checkpoint therapy use into a biomarker-defined, nonoperative management pathway for a subset of rectal cancer patients. It also reinforces FDA’s continued reliance on response durability metrics and central review criteria for accelerated approvals in oncology.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.